SEC Comment Letter for Ocugen, Inc. (OCGN) (CIK 0001372299) (OCGN) — Apr 6, 2020
Ocugen, Inc. (OCGN) (CIK 0001372299)
Date: April 6, 2020 · CIK: 0001372299 · Accession: 0000000000-20-002940
AI Filing Summary & Sentiment
File numbers found in text: 333-237456
Letter
April 3, 2020 Shankar Musunuri, Ph.D., MBA Chief Executive Officer and Chairman Ocugen, Inc. 5 Great Valley Parkway, Suite 160 Malvern, PA 19355 Re:Ocugen, Inc. Registration Statement on Form S-3 Filed March 27, 2020 File No. 333-237456 Dear Dr. Musunuri: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jennifer L. Porter, Esq.
Show Raw Text
April 3, 2020
Shankar Musunuri, Ph.D., MBA
Chief Executive Officer and Chairman
Ocugen, Inc.
5 Great Valley Parkway, Suite 160
Malvern, PA 19355
Re:Ocugen, Inc.
Registration Statement on Form S-3
Filed March 27, 2020
File No. 333-237456
Dear Dr. Musunuri:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at (202) 551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jennifer L. Porter, Esq.